SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Maryanoff BE, Nortez SO, Gardocki JF, Shank RP, Dodgson SP. Anticonvulsant O-alkyl sulfamates in 2,3:4,5-bis-O-(1-methylethylidene)-β-d-fructopyranose sulfamate and related compounds, J Med Chem 1987;30:8807.
  • 2
    Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994; 35:45060.
  • 3
    Pledger G, Reife R, Lim P, Karim R. Overview of topiramate: efficacy from adjunctive therapy trials. Epilepsia 1995;36(suppl 3):S150.
  • 4
    Coulter DA, Sombati S, DeLorenzo RJ. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia 1993;34(suppl 2):S123.
  • 5
    Brown SD, Wolf HH, Swinyard ED, et al. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia 1993;34(suppl 2):S1223.
  • 6
    White HS, Brown SD, Skeen GA, et al. The anticonvulsant topiramate displays a unique ability to potentiate GABA-evoked chloride currents. Epilepsia 1995;36(suppl 3):S39.
  • 7
    Wasserstein A, Reife R, Rak I. Mechanistic basis for topiramate-associated nephrolithiasis: examination of urinary and serum constituents. Epilepsia 1995;36(suppl 3):S153.
  • 8
    Perucca E. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. Epilepsia 1996;37(suppl 2):S813.
  • 9
    Langtry HD, Gillis JC, Davis R. Topiramate: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997;54:75273.
  • 10
    Easterling DE, Zakzewski T, Moyer MD, et al. Plasma pharma-cokinetics of topiramate, a new anticonvulsant in humans. Epilepsia 1988;29:662.
  • 11
    Wu WN, Heebner JB, Streeter AJ, et al. Evaluation of the absorption, excretion, pharmacokinetics and metabolism of the anticonvulsant topiramate in healthy men. Pharm Res 1994;11(suppl):S336.
  • 12
    Bourgeois BFD. Drug interaction profile of topiramate. Epilepsia 1996;37(suppl 2):S147.
  • 13
    Gisclon LG, Curtin CR, Kramer LD. The steady-state (SS) pharmacokinetics (PK) of phenytoin (Dilantin [Rm]) and topiramate (Topamax [Rm]) in epileptic patients on monotherapy, and during combination therapy. Epilepsia 1994;35(suppl 8):S54.
  • 14
    Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997;38:32433.
  • 15
    Doose DR, Walker SA, Pledger G, Lim P, Reife RA. Evaluation of phenobarbital and primidone/phenobarbital (primidone's active metabolite) plasma concentrations during administration of add-on topiramate therapy in five multicenter, double-blind, placebo-controlled trials in outpatients with partial seizures. Epilepsia 1995;36(suppl 3):S158.
  • 16
    Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate and car-bamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996;37:77480.
  • 17
    Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400- and 600-mg daily dosages. Neurology 1996;46:168490.
  • 18
    Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800- and 1000-mg daily dosages. Neurology 1996;46:167883.
  • 19
    Ben-Menachem E, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:53943.
  • 20
    Sharief M, Viteri C, Ben-Menachem E. et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:21724.
  • 21
    Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Epilepsia 1999;40:176774.
  • 22
    Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate mono-therapy for partial onset seizures. Epilepsia 1997;38:294300.
  • 23
    Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999;52:13307.
  • 24
    Elterman RD, Glauser TA, Wyllie E, et al. and the Topiramate YP Study Group. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology 1999;52:133844.
  • 25
    Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999;52:18827.
  • 26
    Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:38999.
  • 27
    Williamson PD, Engel J Jr. Complex partial seizures. In: EngelJJr., PedleyTA, eds. Epilepsy: a comprehensive textbook. Philadelphia : Lippincott-Raven Publishers, 1997:55766.
  • 28
    Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37(suppl 2):S1822.